StemCells (NASDAQ: STEM) recently received a number of ratings updates from brokerages and research firms: 4/28/2016 – StemCells was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Stemcells, Inc. is engaged in research aimed at the development of therapies that would use stem and progenitor […]
